APIMEDS PHARMACEUTICALS US, INC. Stock-Based Compensation
APIMEDS PHARMACEUTICALS US, INC. (APUS) reported Stock-Based Compensation of $1.57 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-05-04.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-05-04
- APIMEDS PHARMACEUTICALS US, INC. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $1.33M.
- APIMEDS PHARMACEUTICALS US, INC. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $42.67K.
- APIMEDS PHARMACEUTICALS US, INC. share-based payment arrangement, noncash expense for fiscal 2025 was $1.57M.
- APIMEDS PHARMACEUTICALS US, INC. share-based payment arrangement, noncash expense for fiscal 2023 was $69.99K.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|
| 2025-12-31 | $1.33M derived: 10-K 12 month − 10-Q 9 month · filed 2026-05-04 | $1.37M derived: sum of 2 quarters · filed 2026-05-04 | $1.57M 10-K · filed 2026-05-04 | |
| 2025-09-30 | $42.67K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $234.73K 10-Q · filed 2025-11-12 | ||
| 2025-06-30 | $192.05K 10-Q · filed 2025-08-19 | |||
| 2023-12-31 | $69.99K 10-K · filed 2025-04-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |